Logo
Corporate International
  • Stem cells
    • Therapeutic Product of Advanced Therapy
    • Mesenchymal stem cells
  • About Institute
    • What are we?
    • Our team
    • Walk on Institute
    • Institute at conferences
    • Diseases treated
  • For Patient
    • Amytotrophic lateral sclerosis (ALS)
    • Rare neurogenerative diseases
    • Self-help book for patients
    • Secondary-progressive multiple sclerosis SPMS
    • FAQ
  • For Doctors
  • News
    • Webinar: Mesenchymal stem cells - current therapeutic trend
    • We confirm efficacy of intrathecal injection of Wharton’s jelly-derived mesenchymal stem cells!
    • ITK researchers validated the international Amyotrophic Lateral Sclerosis Functional Rating Scale
    • Unproven cell-based therapies – what are they? ITK’s position statement
    • We confirm safety of intrathecal injection of Wharton’s jelly-derived mesenchymal stem cells!
  • Contact
    • Write Us
    • Contact details
Corporate International
  • Stem cells
    • Therapeutic Product of Advanced Therapy
    • Mesenchymal stem cells
  • About Institute
    • What are we?
    • Our team
    • Walk on Institute
    • Institute at conferences
    • Diseases treated
  • For Patient
    • Amytotrophic lateral sclerosis (ALS)
    • Rare neurogenerative diseases
    • Self-help book for patients
    • Secondary-progressive multiple sclerosis SPMS
    • FAQ
  • For Doctors
  • News
    • Webinar: Mesenchymal stem cells - current therapeutic trend
    • We confirm efficacy of intrathecal injection of Wharton’s jelly-derived mesenchymal stem cells!
    • ITK researchers validated the international Amyotrophic Lateral Sclerosis Functional Rating Scale
    • Unproven cell-based therapies – what are they? ITK’s position statement
    • We confirm safety of intrathecal injection of Wharton’s jelly-derived mesenchymal stem cells!
  • Contact
    • Write Us
    • Contact details

Diseases
treated

 

Secondary-progressive multiple sclerosis (SPMS)

More

Amytotrophic lateral sclerosis ALS

More

Rare neurodegenerative diseases

More
x

Estonia

Hiszpania (Lab)

Litwa

Luksemburg

Łotwa

Polska (Lab)

Portugalia (Lab)

Rumunia (Lab)

Szwajcaria (Lab)

Turcja (Lab)

Węgry (Lab)

Włochy

Albania

Bośnia i Hercegowina

Chorwacja

Czarnogóra

Dania

Egipt

Kosowo

Macedonia

Niemcy

Serbia

Słowenia

Szwecja

Ukraina

Wielka Brytania

Important information

  • Privacy policy
  • Policy for processing personal data
  • Site map

Your data

  • News
  • Write Us
  • Contact details

Contact

Instytut Terapii Komórkowych S.A.
ulica Warszawska 30,
Building No 7
10-082 Olsztyn
NIP: 7393869683
Tel: +48 895 245 656
Hotline: +48 517 868 949

Copyright © 2020 Polski Bank Komórek Macierzystych. All rights reserved.

remove-2 plus file mail linkedin facebook instagram twitter youtube upload-button

Information about the use of cookies

This website uses cookies. For more information and how to delete cookies, please read our cookie policy See more...